Core Insights - Pfizer is showcasing its commitment to the Chinese market at the 8th China International Import Expo (CIIE) with the theme "Towards the Future with China" [1] - The company emphasizes its alignment with China's 14th Five-Year Plan and the upcoming 15th Five-Year Plan, focusing on innovation and patient care [3][4] - Pfizer's "China 2030 Strategy" aims to accelerate innovation and enhance healthcare accessibility, with significant progress reported in the past year [4][11] Innovation and Product Development - Pfizer's innovative products are expected to benefit over 42 million patients in China by 2024, with a goal of introducing 60 innovative drugs and new indications by 2030 [4] - The company has already achieved over half of this target, with several products receiving NDA approval in China [4] - The global first acute migraine nasal spray, ZavzpretTM, will be showcased at the expo, highlighting Pfizer's commitment to providing new treatment options [5] Collaboration and Ecosystem Development - Pfizer is focused on fostering local scientific innovation and has established partnerships with nearly ten local collaborators in the past year [7][8] - The launch of the Pfizer R&D Open Innovation Center aims to support local partners throughout the drug development process [8] - Strategic agreements, such as the one with 3SBio, enhance Pfizer's oncology pipeline and demonstrate the global competitiveness of local innovations [7] Commitment to Patient Care - Pfizer is dedicated to improving healthcare quality in China, particularly in rural areas, by promoting standardized treatment protocols [11][12] - The company is actively working to ensure that innovative drugs are accessible to patients, collaborating with government and industry partners to reduce medication costs [12] - Initiatives during the expo will focus on enhancing treatment standards for specific patient groups and exploring sustainable patient support ecosystems [12][13]

Core Insights - Pfizer's new antibacterial drug, Sifonuo® (injection of amikacin and avibactam), has been officially approved by the National Medical Products Administration for treating complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) caused by Gram-negative bacteria [1][2] Group 1 - Sifonuo® is the first β-lactam/β-lactamase inhibitor combination that covers all enzyme types of carbapenem-resistant Enterobacteriaceae (CRE), effectively targeting KPC and OXA-48 carbapenemases, and addressing the issue of MBL-producing bacteria [1] - The drug's broad-spectrum enzyme inhibition activity not only improves patient treatment outcomes but also reduces the risk of antibiotic resistance [1] - The approval of Sifonuo® is significant for public health and innovative treatment paradigms, as it helps combat the trend of bacterial resistance and enhances precise coverage against CRE infections [1] Group 2 - Pfizer's China President, Jean-Christophe Pointeau, emphasized the global challenge of antibiotic resistance and the company's commitment to developing innovative anti-infective drugs to address resistant bacterial infections [2] - The approval of Sifonuo® expands the treatment options for carbapenem-resistant Gram-negative bacteria (CRO) and provides innovative solutions for targeted therapy, benefiting more patients [2] - Pfizer expresses gratitude to the National Medical Products Administration and other relevant departments for their support of new antibacterial drugs, reaffirming its mission to bring breakthrough innovations that change patients' lives [2]

Core Insights - Pfizer's new antibacterial drug, Sifonuo® (injection of amikacin and avibactam sodium), has received official approval from the National Medical Products Administration in China [1] Group 1: Product Approval - The drug is approved for the treatment of complex intra-abdominal infections (cIAI) in adults caused by Gram-negative bacteria with limited or no alternative treatment options [1] - It is also indicated for hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) [1]